Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to €495 million ($554 million at the average USD/EUR FX rate of Q1 2022) in continuous R&D funding, upfront and success-based pre-clinical, clinical, regulatory, and commercial milestones, as well as additional royalty payments. Under the terms of the agreement, the companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
This text is a press release from Proxygen. The full text version of the article can be found here.
Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH acted as legal advisor to Proxygen. Dr Marco Stief and Dr Christian Pisani provided the legal advisory services.
